Combination therapy to improve brain function or promote neurogenesis for treating neurodegenerative conditions

Abstract

Disclosed herein are methods and materials for improving brain function and/or promoting neurogenesis in a patient suffering from impaired brain function. Specifically exemplified herein is the co-administration of phenserine and NBI-18.

What is claimed is: 
     
         1 . A method of treating impaired brain function in a patient in need thereof, the method comprising co-administering to the patient phenserine, or pharmaceutically acceptable salt thereof, and stem cell proliferating pyrimidine compound (SCPPC), or pharmaceutically acceptable salt thereof, in respective amounts and frequency such that they work together to improve brain function in the patient. 
     
     
         2 . The method of  claim 1 , wherein phenserine, or pharmaceutically acceptable salt thereof, and SCPPC, or pharmaceutically acceptable salt thereof, are co-administered together by administering a composition containing both. 
     
     
         3 . The method of  claim 2 , wherein the composition comprises a pharmaceutically acceptable carrier. 
     
     
         4 . A method of treating a neurodegenerative disease in a patient in need thereof, said method comprising co-administering to the patient phenserine, or pharmaceutically acceptable salt thereof, and SCPPC, or pharmaceutically acceptable salt thereof, in respective amounts and frequency such that they work together to improve brain function or induce neurogenesis in the patient. 
     
     
         5 . The method of  claim 3 , wherein phenserine, or pharmaceutically acceptable salt thereof, and SCPPC, or pharmaceutically acceptable salt thereof, are co-administered together by administering a composition containing both. 
     
     
         6 . The method of  claim 5 , wherein the composition comprises a pharmaceutically acceptable carrier. 
     
     
         7 . The method of  claim 4 , wherein the patient in need exhibits symptoms of Alzheimer's disease or Parkinson's disease. 
     
     
         8 . A composition comprising phenserine and NBI-18, or pharmaceutically acceptable salts thereof, and a pharmaceutically acceptable carrier. 
     
     
         9 . The composition of  claim 8 , comprising 10-160 mg Posiphen. 
     
     
         10 . The composition of  claim 9 , comprising 100-160 mg Posiphen. 
     
     
         11 . The composition of  claim 9 , comprising 10-600 mg NBI-18. 
     
     
         12 . The composition of  claim 11 , comprising 100-500 mg NBI-18. 
     
     
         13 . The composition of  claim 8 , comprising 10-160 mg Posiphen and 100-500 mg NBI-18. 
     
     
         14 . The composition of  claim 9 , comprising 10-160 mg (−)-phenserine. 
     
     
         15 . The composition of  claim 14 , comprising 100-160 mg (−)-phenserine. 
     
     
         16 . The method of  claim 1 , wherein phenserine is Posiphen. 
     
     
         17 . The method of  claim 1 , wherein phenserine is (−)-phenserine. 
     
     
         18 . The method of  claim 4 , wherein phenserine is Posiphen. 
     
     
         19 . The method of  claim 4 , wherein phenserine is (−)-phenserine. 
     
     
         20 . The composition of  claim 8 , wherein phenserine comprises both Posiphen and (−)-phenserine, or respective pharmaceutically acceptable salts thereof.